Active immunotherapy is the collective term for treatment approaches that train and stimulate your immune system to fight a disease — most commonly cancer — on its own. The word “active” is critical here: rather than introducing ready-made immune cells or antibodies from an external source, these therapies work by mobilising and amplifying your body’s own immune response.
How Is It Different from Passive Immunotherapy?
Understanding this distinction is the clearest way to grasp the concept.
Active immunotherapy gives the body a “recognise and attack” instruction. The immune system generates its own response, and over time that response can strengthen and form long-term immunological memory.
Passive immunotherapy delivers ready-made immune products — such as monoclonal antibodies — directly into the body. The patient’s immune system plays no active role. Effects tend to begin more quickly, but no lasting immune memory is formed.
The Main Types of Active Immunotherapy
Cancer Vaccines
The best-known example is Sipuleucel-T (Provenge), approved for prostate cancer. The patient’s own immune cells are collected, “trained” in the laboratory with tumour antigens, and then reinfused. The body learns to recognise and attack tumour cells going forward.
Checkpoint Inhibitors
These technically fall within active immunotherapy because they work by releasing the immune system’s own brakes, allowing it to act more powerfully. Drugs targeting PD-1, PD-L1, and CTLA-4 — such as pembrolizumab, nivolumab, and ipilimumab — belong to this group. Tumours exploit these checkpoints to put immune cells to “sleep”; the medications disable that mechanism.
CAR-T Cell Therapy
The patient’s T cells are extracted, genetically reprogrammed to recognise the tumour more effectively, multiplied in large numbers, and reinfused. This approach has produced groundbreaking results in leukaemia and lymphoma treatment.
Cytokine Therapies
Substances such as interleukin-2 (IL-2) or interferon — which are natural immune signalling molecules — are administered to directly boost immune activity, increasing both the number and potency of immune cells.
Oncolytic Virus Therapies
Specially engineered viruses are injected directly into the tumour; they both destroy tumour tissue and simultaneously stimulate the immune system. T-VEC (talimogene laherparepvec) is an approved example used in melanoma.
Key Advantages
The most significant feature that sets active immunotherapy apart from conventional treatments is its capacity to generate immunological memory. Even after the treatment course ends, the body may continue to “remember” the tumour and provide protection against relapse. Some patients have achieved complete remissions lasting years — an outcome rarely seen with chemotherapy alone.
Limitations and Important Considerations
Like all treatments, active immunotherapy carries meaningful limitations. It does not work equally well in all patients; the tumour’s immunogenic profile, the patient’s overall immune health, and genetic factors all influence the response. An overstimulated immune system can sometimes turn against healthy tissues — a phenomenon known as immune-related adverse events — which requires careful monitoring and prompt management. Certain therapies, CAR-T in particular, also remain extremely costly and are not yet widely accessible in many healthcare systems.
Where Things Stand Today
Active immunotherapy has become one of the most exciting frontiers in oncology over the past decade. In cancer types that were once considered extremely difficult to treat — advanced melanoma, non-small cell lung cancer, certain leukaemias — durable long-term responses are now being achieved with a regularity that would have seemed remarkable just twenty years ago. Research is advancing rapidly, and the boundaries of what these therapies can do continue to expand.